Research programme: anti-prostate cancer therapeutics - Stem Cell Therapeutics/The University of York
Latest Information Update: 12 Jun 2014
At a glance
- Originator The University of York
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Prostate cancer